BioVersys AG (CH:BIOV)
:BIOV
Want to see CH:BIOV full AI Analyst Report?
BIOV Stock Chart & Stats
CHF29.90
CHF0.68(1.92%)
At close: 4:00 PM EST
CHF29.90
CHF0.68(1.92%)
Day’s Range― - ―
52-Week RangeCHF21.20 - CHF36.00
Previous CloseN/A
Volume262.00
Average Volume (3M)3.74K
Market Cap
CHF154.41M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Sep 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding5,848,743
10 Day Avg. Volume2,578
30 Day Avg. Volume3,744
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF55.00Price Target Upside83.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.6
Revenue Forecast (FY)CHF4.57M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressFirst patient first visit in the global pivotal Phase 3 trial advances BV100's evaluation using mortality and clinical cure endpoints for severe drug-resistant pneumonia.
Pipeline Expansion Via CollaborationExclusive collaboration with Hackensack Meridian Health brings novel ansamycin compounds and early-stage infectious disease expertise, broadening the antibiotic pipeline and increasing chances of a successful candidate.
Regulatory IncentivesBV100's Qualified Infectious Disease Product designation from the FDA makes it eligible for expedited review pathways and extended market exclusivity, improving prospects for accelerated approval and commercial protection.
Bears Say
Commercial Terms ImpactThe partnership's upfront payments and ongoing royalties could diminish BioVersys's share of future revenues and reduce potential returns from successful products.
Regulatory RiskRegulatory submissions for the lead candidate are contingent on a positive pivotal trial readout, creating outcome uncertainty that could delay approval and market entry.
Statistical Power ConcernsAn additional small open-label cohort for the most resistant infections may limit statistical strength for those cases, complicating interpretation of efficacy in the hardest-to-treat patients.
BioVersys AG News
BIOV FAQ
What was BioVersys AG’s price range in the past 12 months?
BioVersys AG lowest stock price was CHF21.20 and its highest was CHF36.00 in the past 12 months.
What is BioVersys AG’s market cap?
BioVersys AG’s market cap is CHF154.41M.
When is BioVersys AG’s upcoming earnings report date?
BioVersys AG’s upcoming earnings report date is Sep 03, 2026 which is in 104 days.
How were BioVersys AG’s earnings last quarter?
BioVersys AG released its earnings results on Apr 01, 2026. The company reported -CHF1.85 earnings per share for the quarter, missing the consensus estimate of -CHF1.07 by -CHF0.78.
Is BioVersys AG overvalued?
According to Wall Street analysts BioVersys AG’s price is currently Undervalued.
Does BioVersys AG pay dividends?
BioVersys AG does not currently pay dividends.
What is BioVersys AG’s EPS estimate?
BioVersys AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVersys AG have?
BioVersys AG has 5,848,743 shares outstanding.
What happened to BioVersys AG’s price movement after its last earnings report?
BioVersys AG reported an EPS of -CHF1.85 in its last earnings report, missing expectations of -CHF1.07. Following the earnings report the stock price went down -0.35%.
Which hedge fund is a major shareholder of BioVersys AG?
Currently, no hedge funds are holding shares in CH:BIOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BIOV Stock 12 Month Forecast
Average Price Target
CHF55.00
▲(83.95% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Newron Pharmaceuticals SpA
―
Santhera Pharmaceuticals Holding
―
RELIEF THERAPEUTICS Holding
―
Options Prices
Currently, No data available
---